The 23 most recent market catalysts affecting $BMY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Market Technicals
Neutral
Impact 55
9 Health Care Stocks Whale Activity In Today’s Session
The filing reports on 'whale' options activity, which refers to large-volume trades by institutional investors or high-net-worth individuals. This activity is significant because i…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 65
Bristol Myers Squibb’s Psoriatic Arthritis Pill Shows Durable Efficacy After Two Years
Bristol Myers Squibb released long-term results from its POETYK PsA-2 trial for Sotyktu, showing durable efficacy and a consistent safety profile over two years for active psoriati…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 65
Bristol Myers Squibb Announces Two-Year Results From Its Phase 3 POETYK PSA-2 Study Showing Durable Efficacy And A Consistent Safety Profile For Sotyktu In Adults With Active Psoriatic Arthritis; Data Build On The Proven Efficacy And Safety Of Sotyktu
Bristol Myers Squibb released two-year data from its Phase 3 POETYK PsA-2 study for Sotyktu, showing sustained efficacy and a favorable safety profile in adults with active psoriat…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 75
Bristol Myers Says Cell Therapy Shows Promise For Heavily Pretreated Blood Cancer Patients
Bristol Myers Squibb's announcement of positive Phase 2 trial results for arlo-cel is a significant corporate catalyst. The experimental cell therapy showed promise in heavily pret…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 75
Bristol-Myers Squibb shares are trading lower after the company announced that its multiple myeloma candidate arlocabtagene autoleucel met primary and secondary endpoints in its phase II QUINTESSENTIAL trial. Investors may be taking pause after the results following an approximately 43% share price gain over the past year.
This headline presents a classic 'buy the rumor, sell the news' scenario for Bristol-Myers Squibb. Despite arlocabtagene autoleucel meeting its endpoints, the stock is trading lowe…
Sep 4, 2026
Corporate Catalyst
Bearish
Impact 75
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths
The filing highlights that Bristol Myers Squibb and Novartis withheld crucial safety information regarding their CAR-T clinical trials for autoimmune diseases, including trial free…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 85
Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment
Bristol Myers Squibb (BMY) secured accelerated FDA approval for Zenbexus (iberdomide) for adult patients with multiple myeloma. This is a significant positive catalyst as Zenbexus …
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
Bristol-Myers Squibb Receives FDA Approval For ZENBEXUS In Combination With Daratumumab And Hyaluronidase-fihj and Dexamethasone For Patients with Multiple Myeloma
Bristol Myers Squibb received FDA approval for ZENBEXUS, a new drug for multiple myeloma. This is significant because ZENBEXUS is the first FDA-approved CELMoD, representing a new …
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Bristol Myers Squibb To Invest $2.3B In Houston Manufacturing Campus, Creating Nearly 500 Jobs
Bristol Myers Squibb is investing $2.3 billion in a new, state-of-the-art manufacturing campus in Houston, Texas, which will create nearly 500 skilled jobs. This investment is part…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
Bristol Myers Squibb shares are trading lower after reports suggesting that the company didn't have any merger discussions with AstraZeneca.
The headline indicates that Bristol Myers Squibb (BMY) shares are trading lower because reports of a potential merger with AstraZeneca (AZN) have been debunked. Merger speculation …
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 90
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus
A media report over the weekend indicated that AstraZeneca and Bristol Myers Squibb are in talks for a massive $400 billion merger. This potential deal is highly significant as bot…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 95
Why Is Bristol-Myers Squibb Stock Surging Monday?
Bristol-Myers Squibb's stock is surging due to reports of advanced merger talks with AstraZeneca, potentially creating a $400 billion pharmaceutical giant. This news is a major cor…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 95
Bristol Myers Squibb shares are trading higher following reports suggesting the company is in discussions to merge with AstraZeneca.
A potential merger between Bristol Myers Squibb and AstraZeneca would be a major corporate catalyst, driving significant volatility and upward pressure on BMY shares due to an expe…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Bristol-Myers Squibb, Raises Price Target to $73
JP Morgan analyst Chris Schott maintained an 'Overweight' rating on Bristol-Myers Squibb (BMY) and raised the price target from $67 to $73. This action signals continued confidence…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to $65
Wells Fargo analyst Mohit Bansal maintained an 'Equal-Weight' rating on Bristol-Myers Squibb (BMY) but raised the price target from $60 to $65. This action signals a slightly impro…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Bristol-Myers Squibb, Raises Price Target to $75
Guggenheim analyst Seamus Fernandez maintained a 'Buy' rating on Bristol-Myers Squibb (BMY) and raised the price target from $72 to $75. This action reflects an analyst's updated p…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 85
Bristol-Myers Boosts 2026 Guidance on Portfolio Strength
Bristol-Myers Squibb's Q2 2026 earnings and sales significantly surpassed analyst expectations, primarily due to strong performance in its 'Growth Portfolio' products like Opdivo Q…
Jul 30, 2026
Macro/Central Bank
Bullish
Impact 65
Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views
This filing provides a comprehensive daily market recap, with Bristol-Myers Squibb's strong earnings serving as a key corporate catalyst. The broader market saw gains, particularly…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 85
Bristol-Myers Squibb Q2 Adj. EPS $2.04 Beats $1.59 Estimate, Sales $12.973B Beat $11.745B Estimate
This headline is a significant corporate catalyst for Bristol-Myers Squibb (BMY). The substantial beat on both adjusted EPS and sales indicates better-than-expected performance, li…
Jul 20, 2026
Corporate Catalyst
Neutral
Impact 75
Bristol Myers Squibb Supercharges Drug Discovery With NVIDIA AI
Bristol Myers Squibb (BMY) is making a substantial investment in AI by deploying NVIDIA's (NVDA) DGX SuperPOD, creating the most powerful AI infrastructure in the life sciences. Th…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 75
Bristol Myers Squibb To Expand Compute Infrastructure To Deploy NVIDIA DGX SuperPOD With DGX Vera Rubin NVL72 Systems
This headline indicates a substantial investment by Bristol Myers Squibb (BMY) into cutting-edge AI infrastructure, specifically NVIDIA's DGX SuperPOD. This move is a strong positi…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 75
Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment
Bristol Myers Squibb announced that the FDA accepted its New Drug Application for mezigdomide, an oral therapy for multiple myeloma, with a target action date in 2027. This is a si…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 75
Bristol Myers Squibb Says FDA Accepts NDA For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Patients With RRMM; PDUFA Date May 13, 2027
Bristol Myers Squibb (BMY) announced the FDA's acceptance of its New Drug Application (NDA) for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refrac…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.